This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nguyen, P. L. Articles by Robertson, M. J. Search for Related Content PubMed PubMed Citation Articles by Nguyen, P. L. Articles by Robertson, M. J.

American Journal of Pathology, Vol 148, 847-853, Copyright © 1996 by American Society for Investigative Pathology

REGULAR ARTICLES

Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease [published erratum appears in Am J Pathol 1996 Jul;149(1):346]

PL Nguyen, NL Harris, J Ritz and MJ Robertson
Department of Pathology Massachusetts General Hospital, Boston 02114, USA.

CD95 (APO-1/Fas) is a member of the superfamily that includes the nerve growth factor and tumor necrosis factor receptors, OX40, CD27, CD30, and CD40. Present on a minority of resting blood lymphocytes, CD95 expression is upregulated on activated T and B lymphocytes and natural killer cells, where binding of the antigen by anti-Fas and anti-APO-1 antibodies has been shown to induce apoptosis. This CD95-mediated apoptosis is at least partially inhibited by expression of the Bcl-2 protooncogene. To evaluate possible roles of CD95 and Bcl-2 in growth regulation of lymphoid neoplasms, we studied by immunohistochemistry the expression of CD95 and Bcl-2 in 67 B- and 5 T-cell lymphomas, and 10 cases of Hodgkin's disease. In all, 29 B and 2 T cell lymphomas, and 9 cases of Hodgkin's disease expressed CD95. Compared with diffuse large B-cell and Burkitt-like lymphomas, lowgrade B-cell lymphomas more frequently expressed CD95 (52% versus 26%; P < .005). None of the B- cell small lymphocytic lymphomas or mantle cell lymphomas expressed CD95, whereas the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocytomas were CD95+. Of the 29 CD95+ B-cell lymphomas, only 33% of the high-grade group coexpressed Bcl-2, compared with 87% of the low-grade group (P < .04). Two of three peripheral T-cell lymphomas--including one anaplastic large cell lymphoma--expressed CD95. Staining for CD95 was seen in 9 of 10 cases of Hodgkin's disease. The infrequent expression of CD95 in high-grade B- cell lymphomas suggests an association between loss of CD95 expression/function and a more aggressive tumor grade. Whereas frequent coexpression of Bcl-2 with CD95 may protect low-grade B-cell lymphomas against CD95-mediated apoptosis, in the high-grade group such coexpression is infrequent, and other regulators besides Bcl-2 may be involved in modulating the apoptosis signal delivered by CD95.

This article has been cited by other articles:

				R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]

				N. C. Briggs, H. I. Hall, E. A. Brann, C. J. Moriarty, and R. S. Levine Cigarette Smoking and Risk of Hodgkin's Disease: A Population-based Case-Control Study Am. J. Epidemiol., December 1, 2002; 156(11): 1011 - 1020. [Abstract] [Full Text] [PDF]

				S. E. Straus, E. S. Jaffe, J. M. Puck, J. K. Dale, K. B. Elkon, A. Rosen-Wolff, A. M. J. Peters, M. C. Sneller, C. W. Hallahan, J. Wang, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis Blood, July 1, 2001; 98(1): 194 - 200. [Abstract] [Full Text] [PDF]

				D. Jones, C. D.M. Fletcher, K. Pulford, A. Shahsafaei, and D. M. Dorfman The T-Cell Activation Markers CD30 and OX40/CD134 Are Expressed in Nonoverlapping Subsets of Peripheral T-Cell Lymphoma Blood, May 15, 1999; 93(10): 3487 - 3493. [Abstract] [Full Text] [PDF]

				K. F. Izban, T. Wrone-Smith, E. D. Hsi, B. Schnitzer, M. E. Quevedo, and S. Alkan Characterization of the Interleukin-1ß-Converting Enzyme/Ced-3-Family Protease, Caspase-3/CPP32, in Hodgkin's Disease : Lack of Caspase-3 Expression in Nodular Lymphocyte Predominance Hodgkin's Disease Am. J. Pathol., May 1, 1999; 154(5): 1439 - 1447. [Abstract] [Full Text] [PDF]

				R. E. Felgar, K. R. Steward, J. B. Cousar, and W. R. Macon T-Cell-Rich Large-B-Cell Lymphomas Contain Non-Activated CD8+ Cytolytic T Cells, Show Increased Tumor Cell Apoptosis, and Have Lower Bcl-2 Expression Than Diffuse Large-B-Cell Lymphomas Am. J. Pathol., December 1, 1998; 153(6): 1707 - 1715. [Abstract] [Full Text] [PDF]

				J. Irsch, S. Nitsch, M.-L. Hansmann, K. Rajewsky, H. Tesch, V. Diehl, A. Jox, R. Kuppers, and A. Radbruch Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues PNAS, August 18, 1998; 95(17): 10117 - 10122. [Abstract] [Full Text] [PDF]

				C. Beltinger, E. Kurz, T. Bohler, M. Schrappe, W.-D. Ludwig, and K.-M. Debatin CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia Blood, May 15, 1998; 91(10): 3943 - 3951. [Abstract] [Full Text] [PDF]